Karpus Management Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 9.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,611 shares of the company’s stock after acquiring an additional 236 shares during the quarter. Karpus Management Inc.’s holdings in Johnson & Johnson were worth $338,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. First Trust Advisors LP raised its holdings in Johnson & Johnson by 61.4% during the 1st quarter. First Trust Advisors LP now owns 523,988 shares of the company’s stock worth $73,248,000 after buying an additional 199,277 shares during the period. Weaver Consulting Group acquired a new stake in Johnson & Johnson during the 1st quarter worth about $741,000. Sphera Funds Management LTD. acquired a new stake in Johnson & Johnson during the 1st quarter worth about $37,044,000. Bath Savings Trust Co raised its holdings in Johnson & Johnson by 6.2% during the 2nd quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock worth $5,888,000 after buying an additional 2,479 shares during the period. Finally, Cox Capital Mgt LLC grew its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock valued at $2,774,000 after acquiring an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 72.05% of the company’s stock.
JNJ opened at $135.17 on Thursday. The business has a 50 day moving average price of $130.30 and a 200 day moving average price of $134.83. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm has a market cap of $344.99 billion, a P/E ratio of 16.52, a price-to-earnings-growth ratio of 2.21 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. During the same period in the previous year, the company earned $2.05 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
Several equities analysts have weighed in on JNJ shares. Wells Fargo & Co lowered their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Friday, October 11th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday. Finally, Barclays initiated coverage on Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price target for the company. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $150.91.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: The role of implied volatility with call option volume
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.